Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension

Jan A Staessen, Robert Fagard, Lutgarde Thijs, Hilde Celis, Guramy G Arabidze, Willem H Birkenhäger, Christopher J Bulpitt, Peter W de Leeuw, Colin T Dollery, Astrid E Fletcher, Françoise Forette, Gastone Leonetti, Choudomir Nachev, Eoin T O’Brien, Joseph Rosenfeld, José L Rodicio, Jaakko Tuomilehto, Alberto Zanchetti, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators*

Summary

Background Isolated systolic hypertension occurs in about 15% of people aged 60 years or older. In 1989, the European Working Party on High Blood Pressure in the Elderly investigated whether active treatment could reduce cardiovascular complications of isolated systolic hypertension. Fatal and non-fatal stroke combined was the primary endpoint.

Methods All patients (≥60 years) were initially started on masked placebo. At three run-in visits 1 month apart, their average sitting systolic blood pressure was 160–219 mm Hg with a diastolic blood pressure lower than 95 mm Hg. After stratification for centre, sex, and previous cardiovascular complications, 4695 patients were randomly assigned to nitrrendipine 10–40 mg daily, with the possible addition of enalapril 5–20 mg daily and hydrochlorothiazide 12·5–25·0 mg daily, or matching placebos. Patients withdrawing from double-blind treatment were still followed up. We compared occurrence of major endpoints by intention to treat.

Findings At a median of 2 years’ follow-up, sitting systolic and diastolic blood pressure differences were systolic 10·1 mm Hg (95% CI 8·8–11·4) and diastolic, 4·5 mm Hg (3·9–5·1). Active treatment reduced the total rate of stroke from 13·7 to 7·9 endpoints per 1000 patient-years (42% reduction; p=0·003). Non-fatal stroke decreased by 44% (p=0·007). In the active treatment group, all fatal and non-fatal cardiac endpoints, including sudden death, declined by 26% (p=0·03). Non-fatal cardiac endpoints decreased by 33% (p=0·03) and all fatal and non-fatal cardiovascular endpoints by 31% (p=0·001). Cardiovascular mortality was slightly lower on active treatment (−27%, p=0·07), but all-cause mortality was not influenced (−14%; p=0·22).

Interpretation Among elderly patients with isolated systolic hypertension, antihypertensive drug treatment starting with nitrrendipine reduces the rate of cardiovascular complications. Treatment of 1000 patients for 5 years with this type of regimen may prevent 29 strokes or 53 major cardiovascular endpoints.

Introduction

The prevalence of isolated systolic hypertension increases with age. Among people aged 70 and older the prevalence is 8%, and it rises to to more than 25% among those aged 80 years or older.1 In 1989, the European Working Party on High Blood Pressure in the Elderly started a placebo-controlled double-blind trial—Systolic Hypertension in Europe (Syst-Eur).2 Active treatment was started with the calcium-channel blocker nitrrendipine,3 with the possible addition of enalapril, hydrochlorothiazide, or both. In 1991, the Systolic Hypertension in the Elderly (SHEP) trial showed that diuretic-based treatment prevented stroke, myocardial infarction, and congestive heart failure.4 Because of the remaining uncertainties about the treatment of isolated systolic hypertension in the elderly,4 the Syst-Eur trial continued after the SHEP results were published.5 Furthermore, controversy about calcium-channel blockers as first-line antihypertensive agents6–10 highlighted the lack of evidence that these drugs reduce cardiovascular risk.

We report the morbidity and mortality results of the Syst-Eur trial. We stopped the trial on Feb 14, 1997, after the second interim analysis because we had reached the primary endpoint of a significant benefit for stroke.1

Methods

The protocol of this trial1 was approved by the ethics committees of the University of Leuven and the participating centres. We used the principles outlined in the Helsinki declaration.11

Patients were recruited from 198 centres in 23 countries across western and eastern Europe. Each centre kept a register of screened patients. Eligible patients were at least 60 years old. On
masked placebo during the run-in phase, their sitting systolic blood pressure ranged from 160 mm Hg to 219 mm Hg, their sitting diastolic blood pressure was below 95 mm Hg, and their standing systolic blood pressure was at least 140 mm Hg. All patients consented to be enrolled, and were available for long-term follow-up. We based the blood-pressure measurements for entry on the averages of six sitting and six standing readings—two in each position at three baseline visits, 1 month apart. Patients were not eligible if systolic hypertension was secondary to a disorder that needed specific medical or surgical treatment. Other exclusion criteria were: retinal haemorrhage or papilloedema; congestive heart failure; dissecting aortic aneurysm; a serum creatinine concentration at presentation of 180 μmol/L or more; a history of severe nose bleeds, stroke, or myocardial infarction in the year before the study; dementia; substance abuse; any disorder prohibiting a sitting or standing position; and any severe concomitant cardiovascular or non-cardiovascular disease.

After stratification by centre, sex, and previous cardiovascular complications, we randomly assigned eligible patients treatment with active medication or placebo by means of a computerised random function. Active treatment was started with nitrendipine and, if necessary, this drug was combined with or replaced by enalapril, hydrochlorothiazide, or both. We aimed to reduce the sitting systolic blood pressure by at least 20 mm Hg to less than 150 mm Hg.2 We used tablets of 20 mg nitrendipine, 10 mg enalapril, and 25 mg hydrochlorothiazide. The dosage steps for nitrendipine were 10 mg in the evening, then 10 mg twice daily, then 20 mg twice daily. For enalapril the dosage steps were 5 mg, then 10 mg, then 20 mg in the evening, and for hydrochlorothiazide, 12·5 mg, then 25 mg in the morning. Placebo tablets were identical to the study drugs, with a similar schedule. For intention-to-treat analysis we maintained open follow-up of the patients who withdrew from treatment.2 During treatment and supervised open follow-up, clinic visits were scheduled every 3 months. For patients who withdrew from treatment for whom regular follow-up was not possible, we annually collected information on vital status, occurrence of major endpoints and other events, and the use of antihypertensive medications (non-supervised open follow-up). Patients without any report within the year before the trial stopped were counted as lost to follow-up.

Our original sample-size calculations assumed a rate of stroke in the placebo group of 17·0 events per 1000 patient-years. 15 000 patient-years (ie, 3000 patients with an average follow-up of 5 years) were required to detect a 40% change in the overall rate of stroke with a two-tailed significance of 1% and 90% power.3 On Aug 18, 1995, the projected number of patients had been recruited (figure 1). However, because in the early phase of the study the stroke rate in the placebo group was only 13·6 events per 1000 patient-years, the steering committee decided in January, 1996, to continue recruitment through 1996 or until at least 4000 patients had been randomly assigned treatment.

The main endpoints were death, stroke, retinal haemorrhage or exudates, myocardial infarction, congestive heart failure, dissecting aortic aneurysm, and renal insufficiency. The endpoint committee, which was unaware of the patients' treatment status, identified all major endpoints by reviewing the patient files and other source documents, or by requesting detailed written information from the investigators, or by both approaches. Endpoints were coded according to the ninth (1975) revision of the International Classification of Diseases.10

Stroke, our primary endpoint, was defined as a neurological deficit with symptoms continuing for more than 24 h or leading to death with no apparent cause other than vascular. Acute myocardial infarction was defined as two of the following three disorders: typical chest pain, electrocardiographic changes, or increased cardiac enzymes.2 Myocardial infarction did not include silent myocardial infarction. Congestive heart failure required the presence of three disorders—symptoms, such as dyspnoea, clinical signs, such as ankle oedema or crepitations, and the necessity of treatment with diuretics, vasodilators, or anti-hypertensive drugs. Sudden death included any death of unknown origin occurring immediately or within 24 h of the onset of acute symptoms, as well as unattended death for which no likely cause could be established by necropsy or medical history. Cardiac events included fatal and non-fatal heart failure, fatal and non-fatal myocardial infarction, and sudden death. Renal insufficiency was diagnosed if at two consecutive visits the serum creatinine concentration reached or exceeded 360 μmol/L or doubled compared with the concentration at randomisation.

All other events were checked at the coordinating office by doctors who were unaware of the treatment-group status. Transient ischaemic attack was defined as focal cerebral dysfunction lasting for less than 24 h, did not lead to withdrawal from double-blind treatment, and was not, therefore, an endpoint.2 Angina pectoris was diagnosed from chest pain, with or without electrocardiographic signs of coronary ischaemia, the need for coronary revascularisation in the absence of acute myocardial infarction, or the indication to start nitrates. Diseases of the large (non-coronary) arteries were ICD-9 codes 433·0–433·9, 440·0–440·9, 442·0–442·9, 443·1, 443·9–444·9, and 447·0–447·9,15 and included surgical or angioplasty procedures on these arteries, but not dissecting aortic aneurysm. Intercurrent diseases were non-fatal non-cardiovascular disorders leading to hospital admission or withdrawal of double-blind treatment or supervised open follow-up. Bleeding disorders excluded cerebral and retinal haemorrhage.

Uncontrolled hypertension was a sitting blood pressure of more than 219 mm Hg systolic or 99 mm Hg diastolic at three consecutive visits while the patients were on the maximum tolerated treatment dose. In January, 1996, on the ethics committee's recommendation, the upper admissible sitting systolic blood pressure at randomisation became 200 mm Hg, but the maximum value during treatment remained 219 mm Hg.

Database management and statistical analysis were done with SAS software, version 6.10. The data were entered in duplicate at the coordinating office (Leuven, Belgium) with systematic quality checks every 3 months. The data were analysed by intention to treat with two-sided tests. We compared means and proportions by standard normal z test and χ² analysis and survival curves by Kaplan-Meier survival function estimates and the log-rank test.

We expected 250 strokes to occur within 5 years. We planned interim analyses after every 50 strokes2 to test for beneficial or adverse events occurring before the end of the trial. Asymmetrical monitoring boundaries, drawn according to the O'Brien-Fleming method,16 allowed us to stop the study for a beneficial effect of active treatment on total stroke at 1% probability or for an adverse effect on any major endpoint at 5%.7 At the second interim analysis in February, 1997, we found a significant decrease in the occurrence of stroke in the active-treatment group that, according to the predefined stopping rules, led us to stop the trial early.

Results
Of 8926 screened patients 6403 (71·7%) were eligible for enrolment in the run-in period (figure 2). 1708 patients...
were not included because of blood pressure values outside the recruitment range (n=910 [53-4%]), withdrawal of consent (n=439 [25-7%]), the presence or occurrence of cardiovascular or non-cardiovascular illnesses, prohibiting randomisation (n=202 [11-8%]), symptoms or treatment with masked placebo (n=55 [3-2%]), on for undocumented reasons (n=333 [19-5%]). 1262 (26-9%) of randomised patients were recruited in Finland, 1044 (22-2%) in Bulgaria, 321 (6-8%) in the Russian Federation, 273 (5-8%) in Belgium, 227 (4-8%) in Italy, 213 (4-5%) in Israel, 210 (4-5%) in the UK, 172 (3-7%) in France, 161 (3-4%) in Estonia, 155 (3-3%) in Lithuania, 139 (3-0%) in Spain, 127 (2-7%) in Poland, and 102 (2-2%) in Romania. Fewer than 100 patients were enrolled in each of Belorussia, the Czech Republic, Croatia, Germany, Greece, Ireland, the Netherlands, Portugal, Slovakia, and Slovenia.

At randomisation, patients in the placebo (n=2297) and active-treatment (n=2398) groups were similar for distribution of sex, age, blood pressure, pulse rate, body mass index, serum cholesterol, the use of tobacco and alcohol, previous cardiovascular complications, and antihypertensive treatment (table 1). Overall, 343 (7-3%) patients (231 men and 112 women) smoked at randomisation and 525 (11-2%) (393 men and 132 women) consumed at least one unit of alcohol per day.

In the two treatment groups combined, 1402 (29-9%) patients had cardiovascular complications at randomisation. 575 (41-0%) and 103 (7-3%) of these patients had symptoms or signs suggestive of coronary heart disease or cerebrovascular disease, respectively. Electrocardiographic changes compatible with left-ventricular hypertrophy were present in 614 patients (43-8%). 110 (7-8%) patients had a combination of these disorders or other vascular, retinal, or renal lesions. Only 58 (4-1%) of 1402 patients had a history of stroke and 163 (11-6%) a history of myocardial infarction.

Patients were recruited over 8 years and median follow-up was 24 months (range 1–97, figure 1). The numbers of patient-years in the placebo and active-treatment groups were 5709 and 5995. Figure 2 shows the status of all patients on Feb 14, 1997, when the trial was stopped.

The proportion of patients started on multiple-drug treatment or proceeding to open follow-up increased faster (p<0.001) in the placebo than in the active treatment group (table 2). At 2 years, nitrendipine or placebo were the only treatments given to 597 (58-9%) of 1014 and 343 (39-6%) of 866 patients, respectively, who stayed on double-blind medication (table 2). Among the patients in open follow-up at 2 years, 65 (36-5%) of 174 randomly assigned active treatment, and 157 (58-1%) of 270 in the placebo group were on antihypertensive drugs, and treatment status with regard to hypertension was undocumented in 88 (49-4%) and 81 (30-0%) patients, respectively.

At 2 years, in the intention-to-treat analysis, the sitting systolic and diastolic blood pressures had fallen by a mean (SD) of 13 (17) mm Hg and 2 (8) mm Hg in the placebo group, and by 23 (16) mm Hg and 7 (8) mm Hg in the active treatment group (figure 3); standing systolic and diastolic blood pressure had fallen by 10 (18) mm Hg and 21 (17) mm Hg, and 7 (9) mm Hg, respectively. At median follow-up, 21-4% of patients in the placebo group and 43-5% in the active treatment group had reached the target blood pressure (p<0.001). At 2 years, the changes in the sitting pulse rate were 0·3 (9·0) beats per min (p=0·25) and 0·2 (8·9) beats per min (p=0·54), respectively. We calculated the differences between groups by subtracting the changes from baseline in the placebo group from the corresponding changes in the active-treatment group. For sitting blood pressure mean between-group differences were 10·1 mm Hg (95% CI 8·8–11·4) systolic and 4·5 mm Hg (3·9–5·1) diastolic at 2 years, and 10·7 mm Hg (8·8–12·5) and 4·7 mm Hg (3·7–5·6) at 4 years. The differences in pulse rate were −0·1 beats per min (−0·8 to 0·6) and −0·6 beats per min (−1·7 to 0·5), respectively.

Uncontrolled hypertension led 126 (5-5%) patients in the placebo group and 11 (0-5%) patients in the active-treatment group (p<0.001) to withdraw from treatment. For 59 and five of these patients, respectively, the blood-pressure criteria applied by the clinical investigator were less stringent than those foreseen by the protocol.

There were fewer deaths from cardiovascular causes in the active treatment group (−27% [−48 to 2], p=0·07) than in the placebo group, but all-cause mortality was not
In the active-treatment group, non-fatal cardiac endpoints decreased by 33% (p=0.03). All fatal and non-fatal cardiac endpoints, including sudden death, decreased by 26% (p=0.03). We found similar trends of reduction for non-fatal heart failure (36%, p=0.06), for all cases of heart failure (29%, p=0.12), and for fatal and non-fatal myocardial infarction (30%, p=0.12; table 4, figure 4).

Active treatment reduced all fatal and non-fatal cardiovascular endpoints by 31% (p<0.001).

Transient ischaemic attacks were not significantly influenced by active treatment (212%, p=0.62; table 5).

The rate of all cerebrovascular events (ie, fatal and non-fatal strokes and transient ischaemic attacks) was 18.0 and 11.8 events per 1000 patient-years (100 cases and 70 cases) in the placebo and active-treatment groups, respectively. Active treatment reduced the rate of all cerebrovascular events by 34% (751 to 257, p=0.006).

Table 2: Follow-up and treatment status by treatment group and year of follow-up

<table>
<thead>
<tr>
<th>Year of follow-up</th>
<th>Total number</th>
<th>Died</th>
<th>Double-blind follow-up</th>
<th>Open follow-up</th>
<th>Lost to follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>All study drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No study drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Only nitrendipine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Study drugs other than</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>nitrendipine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Treatment unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drugs taken</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*In placebo group matching placebos were used. In the active-treatment group, mean daily doses (SD) of nitrendipine, enalapril, and hydrochlorothiazide were 28.2 (12.1) mg, 13.5 (6.2) mg, and 21.2 (6.2) mg, respectively.
†Because many patients were on combined treatment, numbers may not add up.
‡To bridge medical emergencies without having to break code, antihypertensive drugs could be prescribed during double-blind study period for up to 3 consecutive months.
§Patients without follow-up data for more than 1 year.

In the active-treatment group, non-fatal cardiac endpoints decreased by 33% (p=0.03). All fatal and non-fatal cardiac endpoints, including sudden death, decreased by 26% (p=0.03). We found similar trends of reduction for non-fatal heart failure (36%, p=0.06), for all cases of heart failure (29%, p=0.12), and for fatal and non-fatal myocardial infarction (30%, p=0.12; table 4, figure 4). Active treatment reduced all fatal and non-fatal cardiovascular endpoints by 31% (p=0.001).

Transient ischaemic attacks were not significantly influenced by active treatment (−12%, p=0.62; table 5). The rate of all cerebrovascular events (ie, fatal and non-fatal strokes and transient ischaemic attacks) was 18.0 and 11.8 events per 1000 patient-years (100 cases and 70 cases) in the placebo and active-treatment groups, respectively. Active treatment reduced the rate of all cerebrovascular events by 34% (−51 to −11, p=0.006).

Table 3: Mortality by treatment group

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Rate per 1000 patient-years</th>
<th>Difference (active minus placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All causes</td>
<td>24.0 (137)</td>
<td>-14 (−33 to 9)</td>
</tr>
<tr>
<td><strong>Unknown cause</strong></td>
<td>0.4 (2)</td>
<td></td>
</tr>
</tbody>
</table>

Cardiovascular

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Rate per 1000 patient-years</th>
<th>Difference (active minus placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cardiovascular</td>
<td>13.5 (77)</td>
<td>-27 (−48 to 2)</td>
</tr>
<tr>
<td>Stroke</td>
<td>3.7 (21)</td>
<td>-27 (−62 to 2)</td>
</tr>
<tr>
<td>Cardiac mortality†</td>
<td>6.7 (40)</td>
<td>-27 (−61 to 11)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>1.8 (10)</td>
<td>-24 (−70 to 93)</td>
</tr>
<tr>
<td>Coronary mortality†</td>
<td>7.4 (42)</td>
<td>-27 (−64 to 15)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>2.6 (15)</td>
<td>-56 (−82 to 9)</td>
</tr>
<tr>
<td>Sudden death</td>
<td>4.7 (27)</td>
<td>-12 (−49 to 52)</td>
</tr>
<tr>
<td>Dissecting aortic aneurysm</td>
<td>0.4 (2)</td>
<td></td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>0.2 (1)</td>
<td></td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>0.2 (1)</td>
<td></td>
</tr>
</tbody>
</table>

Non-cardiovascular

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Rate per 1000 patient-years</th>
<th>Difference (active minus placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cancer</td>
<td>10.2 (58)</td>
<td>-1 (−31 to 41)</td>
</tr>
<tr>
<td>Cancer</td>
<td>4.4 (25)</td>
<td>-31 (−63 to 26)</td>
</tr>
</tbody>
</table>
could prevent 29 strokes or 53 major cardiovascular events seen in the placebo group, treatment of 1000 elderly patients with isolated systolic hypertension for 5 years.

monotherapy with nitrendipine. Endpoints decreased after randomisation, when most patients were still on placebo. We saw the benefit of active treatment soon after admission to hospital, withdrawal of double-blind treatment, or supervised open follow-up were also similar. 137 placebo-group patients were admitted to hospital because of non-cardiovascular disorders compared with 145 in the active-treatment group (25·3 v 25·4 admissions per 1000 patient-years, p=0·95).

Figure 4: *Cumulative rates of fatal and non-fatal stroke and myocardial infarction by treatment group*

Vol 350 • September 13, 1997 761

The rates of angina pectoris (−24%, p=0·04) and peripheral arterial disease (−32%, p=0·06) were slightly lower in the patients on active treatment (table 5). The occurrence of cancer, benign neoplasm, and bleeding, excluding cerebral and retinal haemorrhage, was similar in both treatment groups (table 5). The rates of intercurrent diseases of non-cardiovascular origin, which led to admission to hospital, withdrawal from double-blind treatment, or supervised open follow-up were also similar. 137 placebo-group patients were admitted to hospital because of non-cardiovascular disorders compared with 145 in the active-treatment group (25·3 vs 25·4 admissions per 1000 patient-years, p=0·95).

Discussion

The antihypertensive drugs used in our trial were the dihydropyridine calcium-channel blocker nitrendipine, the converting-enzyme inhibitor enalapril, and the thiazide diuretic hydrochlorothiazide. Among elderly patients with isolated systolic hypertension, these drugs reduced the risk of stroke and the occurrence of various other cardiovascular complications. We saw the benefit of active treatment soon after randomisation, when most patients were still on monotherapy with nitrendipine. Endpoints decreased similarly in eastern and western European patients. At the rates seen in the placebo group, treatment of 1000 elderly patients with isolated systolic hypertension for 5 years could prevent 29 strokes or 53 major cardiovascular events.

The benefits of antihypertensive treatment were similar to those in six other trials17-22 in older patients with combined systolic and diastolic hypertension. Overall, in these trials antihypertensive treatment reduced fatal stroke by 33% and cardiovascular mortality by 22%.23 In a subsequent quantitative review,24 which also included the SHEP trial,4 the estimates were the same.

Although the relative benefit of antihypertensive treatment is constant for a wide range of risks, absolute benefit varies according to the risk of events seen in the placebo group.24 Of seven intervention trials 4,17-19,21,22,25 the smallest absolute benefit was seen in the Medical Research Council trial in young hypertensive patients with diastolic hypertension and the largest in the Swedish Trial in Old Patients with Hypertension (STOP).25 Per 1000 patients treated for 5 years, the number of strokes and cardiovascular deaths prevented in those two trials ranged from two to 27 and from six to 67, respectively. The absolute number of strokes prevented by active treatment in our trial was similar to that in the STOP trial, whereas the number of cardiovascular deaths potentially prevented was half-way between the Medical Research Council trial and STOP results. Our results for stroke and myocardial infarction were similar to those of the SHEP trial.4 Active treatment with a thiazide combined with atenolol or reserpine decreased these endpoints by 36% and 27%, respectively.23

We recruited patients from eastern and western Europe. Of 8926 screened patients, 4695 (52·6%) were randomised. We recruited patients by population...
screening, from family practices, and at primary and secondary referral centres. We included only 1.2% of patients with previous myocardial infarction and 3-5% with a history of stroke. The exclusion of patients with major cardiovascular complications and the selection of individuals likely to comply with long-term follow-up and treatment are factors that must be taken into account when the results are extrapolated. In the SHEP trial, 447921 individuals were contacted, mainly by mass mailing and community screening. Of these 11.6% met the initial criteria, 2.7% completed the baseline visit, and 1.1% (n=4736) were randomly assigned treatment. Among those patients the maximum diastolic blood pressure at randomisation was 5 mm Hg lower than in our study. Despite these differences in recruitment and selection criteria, total and cardiovascular mortality in the placebo groups of the SHEP trial and our trial were similar (ie, 23 vs 24 deaths and 10 vs 13 deaths per 1000 patient-years).

The role of the newer classes of antihypertensive drugs in the pharmacological treatment of uncomplicated hypertension continues to be debated. According to the 1993 guidelines in the USA, diuretics and β-blockers are the only types of drugs that have been used in long-term controlled clinical trials and shown to reduce morbidity and mortality. These drugs have been, therefore, recommended as first-choice agents unless they are contraindicated or unacceptable or there are special indications for other agents. By contrast, a joint committee of WHO and the International Society of Hypertension believed that, although most clinical trials tested diuretics, centrally acting drugs, vasodilators, or β-blockers, often in combination, no evidence was available that the benefits were due to any particular class of antihypertensive drug rather than to the lowering of blood pressure per se. The committee recommended that several drugs may be prescribed as first-line treatment of mild sustained hypertension. They listed the drugs in order of proven benefit on morbidity and mortality as: diuretics, β-blockers, and converting-enzyme blockers, calcium-channel blockers, and α-adrenoceptor-blocking drugs. Although both sets of guidelines differed in their approach to designating first-line antihypertensive agents, they both recognised the urgent need to assess the efficacy of calcium-channel blockers and converting-enzyme inhibitors in reducing long-term morbidity and mortality in the treatment of hypertension. We provide evidence that the newer antihypertensive drugs also improve prognosis in a large subset of the hypertensive population.

Two previous studies investigated the effects of nifedipine in Chinese hypertensive patients, but followed unorthodox designs. The Cheng-Du nifedipine trial was a prospective placebo-controlled trial of 683 hypertensive patients. During the 6 years of follow-up, the rate of cardiovascular events decreased from 14.0% to 5.2% (p=0.05). The Shanghai Trial of Nifedipine in the Elderly (STONE) was a single-blind trial in which 1797 patients were assigned either nifedipine (20-60 mg/day) or placebo, with the possible addition in both treatment groups of active captopril (20-50 mg/day) or hydrochlorothiazide (25 mg/day). Patients whose diastolic blood pressure exceeded 110 mm Hg were reassigned nifedipine. Total stroke incidence decreased by 57% (95% CI –23 to –76). In the nifedipine group total mortality declined by 45% (~71 to 3). No significant changes were seen in cardiovascular mortality (~26% [–66 to 62]) and in the rate of fatal and non-fatal myocardial infarction (~6% [–87 to 56]).
A case-control study of measles vaccination and inflammatory bowel disease

Mark Feeney, Andrew Clegg, Paul Winwood, Jonathon Snook, for the East Dorset Gastroenterology Group*

Summary

Background The cause of inflammatory bowel disease (IBD) remains to be established. Evidence has linked measles infection in early childhood with the subsequent risk of developing IBD, particularly Crohn’s disease. A cohort study raised the possibility that immunisation with live attenuated measles vaccine, which induces active immunity to measles infection, might also predispose to the later development of IBD, provoking concerns about the safety of the vaccine.

Method We report a case-control study of 140 patients with IBD (including 83 with Crohn’s disease) born in or after 1968, and 280 controls matched for age, sex and general practitioner (GP) area, designed to assess the influence of measles vaccination on later development of IBD. Documentary evidence of childhood vaccination history was sought from GP and community health records.

Findings Crude measles vaccination rates were 56–4% in patients with IBD and 57·1% among controls. Matched odds ratios for measles vaccination were 1·08 (95% CI 0·62–1·88) in patients with Crohn’s disease, 0·84 (0·44–1·58) in patients with ulcerative colitis, and 0·97 (0·64–1·47) in all patients with IBD.

Interpretation These findings provide no support for the hypothesis that measles vaccination in childhood predisposes to the later development of either IBD overall or Crohn’s disease in particular.


*Listed at the end of the paper

Department of Gastroenterology, Poole Hospital, Dorset BH15 2JB, UK (M A Feeney MD, A Clegg PhD); Department of Gastroenterology, Royal Bournemouth Hospital, Dorset (P J Winwood MRCP); and NHS Centre for Reviews and Dissemination, University of York, York (A J Clegg PhD)

Correspondence to: Dr Jonathon Snook

Introduction

The possibility that the inflammatory bowel diseases (IBDs)—ulcerative colitis and Crohn’s disease—are caused by a transmissible agent such as a virus is an attractive hypothesis.1 Wakefield and colleagues have suggested that Crohn’s disease might be the late result of measles virus infection at a critical time during early childhood. This “measles hypothesis” is based on a series of pathological and epidemiological studies.2-4

Wild-type measles infection is associated with substantial morbidity and mortality. In the developed world, complications occur in about one in 15 infections, and most deaths result from the development of pneumonia, acute encephalitis, or the rare but relentlessly progressive subacute sclerosing panencephalitis.5,6 Live attenuated measles vaccine was introduced in the UK in 1968, and as a result of the vaccination campaign the incidence of measles infection and complications has fallen strikingly.7,8

The measles hypothesis has been embolished with evidence from a cohort study suggesting an increased risk of IBD in individuals given live attenuated measles vaccine in early childhood.7 This report has led to concern about the safety of measles vaccination and resulted in some parents declining an effective vaccine. Counselling has been particularly difficult because the evidence on which to base reassurance on this issue is very limited.9

The present investigation was devised to assess the risk of IBD associated with vaccination against measles in early childhood. A case-control design was used because of the relative rarity of the disease and the frequency of vaccine exposure in the population.10,11 The study focuses on the period between 1968 and 1991, during which measles vaccination was routinely offered and immunisation status documented in the UK by general practitioners (GPs) and community health services within the National Health Service. National uptake rates for measles vaccination ranged from 34% in 1968 to 90% in 1991.12

Method

This case-control study was done in East Dorset, UK, with the approval of the local research ethics committee. 164 patients with a definite diagnosis of IBD on the basis of standard clinical